ICOSAVAX INC (ICVX) Stock Price, Quote, News and Overview
NASDAQ:ICVX - Nasdaq - US45114M1099 - Common Stock - Currency: USD
ICVX Quote, Performance and Key Statistics
15.31
-0.14 (-0.91%)
The current stock price of ICVX is 15.31 USD. In the past month the price decreased by -0.78%. In the past year, price increased by 68.8%.
ICVX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About ICVX
Company Profile
Icosavax, Inc. engages in the development and commercialization of vaccines against infectious diseases. The company is headquartered in Seattle, Washington and currently employs 60 full-time employees. The company went IPO on 2021-07-29. The firm uses its virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with a focus on life-threatening respiratory diseases. Its VLP platform technology is designed to enable multivalent, particle-based display of complex viral antigens. Its pipeline includes vaccine candidates targeting viral causes of pneumonia. The company is developing these candidates for older adults, a patient population with high unmet need. Its lead vaccine candidate, IVX-A12, is a bivalent candidate, or a mixture of two different VLP candidates. IVX-A12 combines IVX-121, a vaccine candidate designed to target respiratory syncytial virus (RSV), and IVX-241, a vaccine candidate designed to target human metapneumovirus (hMPV). The company is also developing additional vaccine candidates as part of its strategy to develop combination VLP vaccines targeting the viral causes of pneumonia in older adults, including influenza and SARS-CoV-2.
Company Info
ICOSAVAX INC
1930 Boren Ave., Suite 1000
Seattle WASHINGTON US
CEO: Adam Simpson
Employees: 60
Company Website: https://icosavax.com/
Phone: 12067370085
ICOSAVAX INC / ICVX FAQ
What is the stock price of ICOSAVAX INC today?
The current stock price of ICVX is 15.31 USD. The price decreased by -0.91% in the last trading session.
What is the ticker symbol for ICOSAVAX INC stock?
The exchange symbol of ICOSAVAX INC is ICVX and it is listed on the Nasdaq exchange.
On which exchange is ICVX stock listed?
ICVX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ICOSAVAX INC stock?
12 analysts have analysed ICVX and the average price target is 18.87 USD. This implies a price increase of 23.25% is expected in the next year compared to the current price of 15.31. Check the ICOSAVAX INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ICOSAVAX INC worth?
ICOSAVAX INC (ICVX) has a market capitalization of 766.88M USD. This makes ICVX a Small Cap stock.
How many employees does ICOSAVAX INC have?
ICOSAVAX INC (ICVX) currently has 60 employees.
What are the support and resistance levels for ICOSAVAX INC (ICVX) stock?
ICOSAVAX INC (ICVX) has a support level at 15.31 and a resistance level at 15.73. Check the full technical report for a detailed analysis of ICVX support and resistance levels.
Is ICOSAVAX INC (ICVX) expected to grow?
The Revenue of ICOSAVAX INC (ICVX) is expected to decline by -100% in the next year. Check the estimates tab for more information on the ICVX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ICOSAVAX INC (ICVX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ICVX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ICVX, evaluating the profitability, health, valuation and growth aspects
- ICOSAVAX INC (ICVX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ICOSAVAX INC (ICVX) Sales and EPS estimates to see what analysts future expectations are.
- ICOSAVAX INC (ICVX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ICOSAVAX INC (ICVX) Insider and Institutional Ownership to learn about the owners and their transactions.
- ICOSAVAX INC (ICVX) Stock Chart to make your own analysis
- ICOSAVAX INC (ICVX) Latest news and press-releases to stay up to date.
Does ICOSAVAX INC (ICVX) stock pay dividends?
ICVX does not pay a dividend.
What is the Price/Earnings (PE) ratio of ICOSAVAX INC (ICVX)?
ICOSAVAX INC (ICVX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.22).
ICVX Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to ICVX. When comparing the yearly performance of all stocks, ICVX is one of the better performing stocks in the market, outperforming 94.46% of all stocks.
ICVX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ICVX. While ICVX has a great health rating, there are worries on its profitability.
ICVX Financial Highlights
Over the last trailing twelve months ICVX reported a non-GAAP Earnings per Share(EPS) of -2.22. The EPS decreased by -1.83% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -38.48% | ||
| ROE | -41.61% | ||
| Debt/Equity | 0 |
ICVX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 78% to ICVX. The Buy consensus is the average rating of analysts ratings from 12 analysts.
For the next year, analysts expect an EPS growth of 5.52% and a revenue growth -100% for ICVX